Señales en vivo de NBSE | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 may 2024 @ 16:00):

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes...

Stats
Volumen de hoy	54 912.00
Volumen promedio	249 496
Capitalización de mercado	1.46M
EPS	$0 ( 2024-05-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0.00700 (1.79%)

Insider Trading

Date	Person	Action	Amount	type
2022-12-31	Symetryx Corp	Buy	0
2023-09-14	Symetryx Corp	Sell	129 108	Common Stock, Par Value $0.0001 per Share
2023-09-15	Symetryx Corp	Sell	103 337	Common Stock, Par Value $0.0001 per Share
2023-09-18	Symetryx Corp	Sell	50 000	Common Stock, Par Value $0.0001 per Share
2023-08-23	Symetryx Corp	Sell	0	Common Stock, Par Value $0.0001 per Share

INSIDER POWER
-20.26
Last 87 transactions
Buy: 13 371 397 \| Sell: 4 577 643

NeuBase Therapeutics Inc Correlación

10 Correlaciones Más Positivas
LIAN	0.874
ATER	0.869
BPOPN	0.843
BIMI	0.829
LEGH	0.825
CDMOP	0.809
EQIX	0.808

10 Correlaciones Más Negativas
VMCAU	-0.856
OSN	-0.855
HSON	-0.827
LWAY	-0.822
ALR	-0.82
VFF	-0.81

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NeuBase Therapeutics Inc Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$-1.26M (0.00 %)
EPS:	$-21.08

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-1.26M (0.00 %)
EPS:	$-21.08

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.930

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.890

Financial Reports:

No articles found.

NeuBase Therapeutics Inc

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.